Henry Schein outlines 2026 EPS of $5.29-$5.39 as it lifts sales growth outlook to 4.5%-5.5% (NASDAQ:HSIC)

Henry Schein (HSIC) raised full-year 2026 earnings guidance to $5.29–$5.39 per share, signaling management confidence in operational execution and market demand for dental and healthcare distribution. This upward revision reflects improved visibility into revenue growth and margin expansion, positioning the company ahead of prior expectations and suggesting operational leverage is materializing across segments.

The acceleration of sales growth guidance to 4.5%–5.5% indicates Dentrix Ascend—the company's cloud-based practice management platform—is driving both organic growth and customer stickiness. Coupled with announced cost initiatives, management has identified structural efficiencies that support bottom-line accretion without sacrificing top-line momentum. This margin-expansion narrative reflects pricing power and operational discipline in a consolidated healthcare distribution landscape.

The Q2 earnings call recap suggests demand resilience in both dental and medical supply channels, countering concerns about healthcare cost pressures. HSIC's ability to guide higher while executing cost programs demonstrates pricing resilience and operational leverage—key markers of competitive moat durability in the healthcare services infrastructure space.

Sector implication: This guidance beat and margin narrative favors Health Care equipment and distribution subsectors, supporting a thesis that essential healthcare distribution benefits from consolidation, digital transition (Ascend), and secular growth in preventive care utilization. Strong earnings beats in this space may attract rotation toward defensive healthcare plays with pricing power.